Big Pharma Split Corp.

December 31, 2023

Management Report of Fund Performance

Big Pharma Split Corp.

PRESIDENT'S MESSAGE

Unitholder Letter March 2024

Dear Valued Investor,

Thank you for placing your trust and confidence in Harvest's investment products through 2023. We follow a philosophy that held strong in our ETFs and Funds in the past year, and one we will remain committed to going forward.

Harvest Portfolios Group Inc. and its growing group of Harvest ETFs have remained steadfast in making equity investments since our launch in 2009. This is by design to take advantage of the long-term growth in capital markets, the growth of industries and the growth of well-positioned and well-managed companies. We couple that philosophy with a finely tuned proprietary cover call option writing strategy that has proven to generate steady and attractive levels of consistent monthly cashflows for unitholders. We are proud to say that in the coming year we will surpass 10 years of option writing as part of our strategy.

In late September 2023 we added a new category to our product line up with the launch of the Harvest Premium Yield Treasury ETF (TSX: HPYT). This launch into the fixed income arena is due to what we believe is a topping of the interest rate cycle which pairs well with our option writing strategy to generate additional income. Investing in large and mega cap U.S. Treasury Bond ETFs enables us to capitalize on our option writing strategy on those securities.

The year was tough to navigate as rates pushed ever higher and markets reacted negatively. Other than cash assets, it was difficult for assets to get through the year unscathed. Throughout the year we continued to write options, which helped us manage through some choppy waters. Defensive areas like healthcare and utilities were hit harder than expected while some areas - like technology - did very well. As we rolled into the final months of 2023, the markets began to rebound as the US Federal Reserve softened their language on interest rates.

On a brighter note, Harvest Tech Achievers Growth & Income ETF (Class U) was named "**Best Sector Equity Fund over 5 years**" by Refinitiv Lipper Funds Awards Canada for the second year in a row (the Class A version of the ETF was also a winner last year). This was on top of a distribution increase, the third in that ETFs history.

As we look ahead to 2024, we remain steadfast in our philosophy of choosing long term growth industries or mega-trends. Our outlook on these industries is framed by our orientation towards high quality companies and long-term trends.

As an investment fund manager, we make investment decisions based on industry and business fundamentals. We do not let shorter-term economic indicators influence our view of a company and why it is in the portfolio. We choose the industry first, choose where we think the puck is going, then drill down and start to find the standout businesses that can expand in those industries.

Investing is not static, and we have to fine tune and make changes from time to time. In general, when we take a position, it is to hold for the longer term. That could mean holding a position for five years or more, especially in our equity income ETFs. Using this prudent and tactical approach helps us stick to our investment philosophy and deliver returns for unitholders in our ETFs and Funds.

Let me again thank you for your support and confidence in the Harvest team and our products. Let me assure you that we will remain steadfast in our management and development of products to meet the needs of investors for both income and growth.

Sincerely,

Signed "Michael Kovacs"

Michael Kovacs,

President and Chief Executive Officer

Big Pharma Split Corp.

CORPORATE OVERVIEW

Harvest Portfolios Group Inc. (“Harvest” or the “Manager”) is a Canadian Investment Manager founded in 2009. Harvest is focused on developing investment products that follow three investment criteria.

We (i) endeavor to develop investment products that are clear in their mandate and easy for investors to understand, (ii) strive to be transparent so that our investors can review their financial reports and know exactly what they own and (iii) seek to provide investors with consistent monthly or quarterly income by investing the fund portfolios in well managed companies that have a steady cash flow and dividend-paying history.

MANAGEMENT DISCUSSION OF FUND PERFORMANCE

The annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the Big Pharma Split Corp. (the"Company" or "Fund"). You can get a copy of the annual financial statements at your request, and at no cost, by calling toll free at 1-866-998-8298; by writing to us at Harvest ETFs, 610 Chartwell Rd, Suite 204, Oakville, Ontario, L6J 4A5; or by visiting our website at **www.harvestetfs.com**; or on SEDAR+ at **www.sedarplus.ca**.

Unitholders may also contact us using one of these methods to request a copy of the Fund’s proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

INVESTMENT OBJECTIVES AND STRATEGY

The Fund invests, with equal weighting as a percentage of net asset value of the Fund, in equity securities of 10 issuers, primarily from the pharmaceutical sector and that have the largest market capitalization, with the objectives of providing:

(i) holders of Preferred shares a fixed cumulative preferential quarterly cash distributions in the amount of $0.125 per Preferred share ($0.50 per annum or 5.0% per annum on the issue price of $10.00 per Preferred share) until December 31, 2027 (the “Maturity Date”) and to return the original issue price of $10.00 to holders on the Maturity Date.

(ii) holders of Class A shares a regular monthly noncumulative cash distributions targeted to be $0.1031 per Class A share representing a yield on the issue price of the Class A shares of 8.25% per annum on the issue price of $15.00 per Class A Share and to provide holders with the opportunity for growth in the net asset value per Class A share.

The Fund is reconstituted and rebalanced quarterly to include issuers that: (i) are listed on a North American exchange; (ii) pay a dividend; and (iii) have options in respect of its equity securities that, in the opinion of the Manager, are sufficiently liquid to permit the Portfolio Manager to write options in respect of such securities.

To achieve its investment objective, the Fund will invest in eight of the ten largest pharmaceuticals issuers taken from an universe of equity securities selected by the Manager of the Fund. The remaining two equity securities also come from the universe of equities selected by the Manager of the Fund. The Fund may invest in American Depository Reciepts of pharmaceutical and healthcare issuers that are not listed on a Canadian stock exchange. All other securities held by the Fund will be common shares of pharmaceutical and healthcare issuers. The Fund's excess cash will be used to increase exposure to issuers with less than the average weight of the Fund.

RISK

The risks associated with investing in the Fund are as described in the prospectus. There were no material changes to the Fund over the year ended December 31, 2023 (the "Period") that affected the overall level of risk of the Fund.

RESULTS OF OPERATIONS

Overall Performance

The Fund's return by share type compared to the MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)$^{\pm}$ for the Period is as follows:

	Return %
Class A shares	(3.42)
Preferred shares	5.09
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)$^{\pm}$	3.30

The primary reason for the divergence is that the Fund is concentrated in only 10 securities.

The Fund was invested in 8 of the largest pharmaceutical issuers by market capitalization and two large capitalization biotechnology stocks listed on a North American exchange.

The Preferred shares provide their holders with a fixed cumulative preferential quarterly cash distribution in the amount of $0.125 per share (subject to net asset value minimums) and as a result of the priority of the Preferred shares, the expenses of the Company are borne by Class A shareholders. Performance of the Preferred shares is equivalent to the fixed distribution whereas the Class A shares performance is impacted by the capital appreciation (depreciation) and expenses over and above the preferential return of the Preferred shares. As a result, the performance of the Class A shares can vary significantly from the Preferred shares.

Factors Affecting Fund Results

For 2023, the Healthcare sector lagged the broader equity market performance, representing a reversal from what happened in 2022, when it was a leader. For context, the broader market recovered from what was a relatively significant poor performance in 2022 with the 2023 strong performance skewing mainly towards Technology, Communications and select Consumer Discretionary stocks.

There were no material changes to the sub-sector allocations in the Fund during the Period.

The individual stocks within the Fund did not perform uniformly, as certain stock specific catalysts drove their relative performance. Specifically, the difference between the top and bottom performers was very wide within the sub-sector and among individual stocks.

Clinical trial results for diabetes and weight loss treatments across the industry highlighted the potential for a very large market and benefitted the top performing position in the Fund, Eli Lilly and Company, a market leader in this therapeutic area. On the other hand, Bristol-Myers Squibb Company saw increased competition coupled with concerns surrounding loss of exclusivity in certain drugs later in the decade; and industry stalwart Johnson & Johnson slowed mainly due the general market conditions with some negative impact emanating from the spin out of their consumer products division. The varied underlying performance and key stock catalysts highlight the benefits of diversification while still being concentrated in the sub-sector with a portfolio of 10 large capitalization stocks.

RECENT DEVELOPMENTS

Potential Impact for the Fund

In the shorter-term, the macro environment (both economic and geopolitical), while appearing to be stabilizing, continues to have some uncertainty. Inflationary pressures appear to be subsiding and expectations that central banks will not increase rates further have continued to be a source of reprieve for the broader markets. Nonetheless, inflationary pressures and potential for interest rate increases can change quickly based on economic data.

Global geopolitical tensions remain elevated through the end of the Period and remain as a source of uncertainty for broader markets. The conflict in Eastern Europe following the Russian invasion of Ukraine in February 2022 continued during the Period. Also, in October of 2023, a Hamas led Palestinian militant group attacked Israel triggering a major and ongoing conflict that continued through the end of the Period.

Regardless of the shorter-term macro environment outlook, the primary long-term drivers for the Health Care, and the Pharmaceuticals sub-sector over the medium-longer term remain intact: global aging populations, developing markets, and technological innovation (both across devices and bio/pharmaceutical drugs). These medium- to longer-term drivers form the basis of our positive view on the sub-sector while it is also well positioned to withstand some of the shorter-term macro uncertainty that may persist and positioned to participate in the upside recovery as the breadth of participation continues to expand across the broader markets.

2023 Market Review

To combat inflation, central banks around the world aggressively started raising interest rates in 2022 to rates well above what the markets were expecting. This along with the geopolitical instability that occurred during the Period, resulted in the significant negative returns that the broader global and U.S. equity markets experienced in the previous year, 2022.

At the turn of 2023, the US equity markets offered some initial reprieve and ultimately finished 2023 with strong positive returns. During this Period, the market was significantly volatile and saw returns highly concentrated in a few large companies. The latter did not bode well for diversified investors and sometimes gave the feeling of a bear market. While select large companies were a key driver of the overall market performance given their relatively very strong performance, the breadth of participation across stocks and sub-sectors expanded over the course of the Period with the overall market returns finishing above average.

The significant volatility experienced by markets came from a wide variety of economic and geopolitical factors as well as sector specific turmoil within the banking sector. Notably, there were two short periods in which returns for the S&P 500 fell by double digits.

The first happened in March when depositors of Silicon Valley Bank ("SVB") began withdrawing their funds forcing the bank to realize significant losses on its investments in securities and together set off further withdrawals. This eventually led to the failure of SVB and triggered a flurry of withdrawals at another large regional bank, Signature Bank of New York (SBNY). Investors became altered to the risk of contagion, which produced much uncertainty and pressured the stock returns of both banks and insurance companies throughout the remainder of the Period, with some modest reprieve toward the end.

There were echoes of the Great Financial Crisis of the past that temporarily depressed sentiment in the broader markets through March. This later retreated as investor excitement over the promise of artificial intelligence ("AI") abounded. Notably, ChatGPT-3 became a topic of focus among investors and media alike. A string of new "generative AI" focused product announcements from several major software companies and culminating with a strong earnings reports ignited a buying frenzy for stocks of companies perceived to be beneficiaries of the AI theme. This marked a pivot for sentiment in the broader equity markets and inspired optimism for technology and more consumer growth focused areas, such as travel related companies, that generally continued through the Period.

The second period of meaningful volatility occurred towards the end of the summer period as concerns around persistent inflation resurfaced. Concerns about headline inflation remaining elevated fueled interest rate increases globally by central banks and specifically the Federal Reserve in the United States (the "Fed") and resulted in accelerated rises in government bond yields across maturities. Despite many leading indicators, such as supply chain congestion indicators, suggesting that the trend was towards normalizing inflation levels, longer dated U.S. Treasury bond yields continued to move higher amidst speculation that the inflation was not yet under control. During this Period, longer dated U.S. Treasury Bond yields gapped higher through 5% in a very short period, causing what appeared to be some dislocation in the fixed income markets, and that flowed through to causing uncertainty around how high rates may go and served as a further catalyst for equity market volatility.

During the Fall, the tone of the Fed on carrying out further interest increases shifted as economic data including inflation, showed signs that the pervious interest hikes in the past 18 months began to take effect. The Fed's new tone suggested a pause was warranted given the economic data. This caused the broader equity markets to stabilize and start to recover through the end of the Period. Treasury bond yields halted the seemingly unstoppable upward trajectory and started to retrace lower, providing much needed reprieve to the dislocated fixed income markets.

Some of the sectors that outperformed during the bear market of 2022, such as Utilities and Health Care, lagged during the Period with investors continuing to shift back towards higher growth areas of the market. The Energy sector also saw negative returns during the Period as signs of slowing global economic growth and fading headlines about energy security due to the war in Ukraine led to a fall in oil prices. Geopolitical tensions continued to escalate in the latter part of the year, resulting in new threats of potential supply disruptions; commodity prices reversing course; and a slowdown in demand fundamentals that seemingly outweighed potential supply disruptions. Other sectors such as Information Technology, on the other hand, significantly outperformed the market during the Period.

RELATED PARTY TRANSACTIONS AND OTHER EXPENSES

Management fees
The Fund pays the Manager a management fee calculated based on the average daily net asset value ("NAV") and paid monthly in arrears, based on an annual rate of 0.75%, plus applicable taxes, of the NAV of the Fund. For these purposes, the Preferred shares are not considered a liability of the Fund. At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

Operating expenses
The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of units, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee ("IRC"), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

Other expenses
The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to unitholders and other unitholder communications; a reasonable allocation of salaries and benefits; and other administrative expenses and costs incurred in connection with the Fund's ongoing operations. These expenses are allocated by the Manager on a reasonable basis, across all the Harvest Portfolios Group Inc. funds, and classes of each applicable fund. These expenses were $8,064 for the Period and are included in the unitholder reporting costs on the Statement of Comprehensive Income (Loss) in the financial statements.

Waivers and absorptions
At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. There were no management fee waivers or expense absorptions for the Period.

The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

Issue costs
Certain Offering expenses such as costs of creating the Fund, the cost of printing and preparing the prospectus, legal expenses of the Fund, agent's fees payable by the Fund, out-of-pocket expenses incurred by the agents as well as brokerage commissions charged on trades under the ATM program are included in the carrying amount of the Fund's obligation for net assets attributable to holders of redeemable Class A shares. As a result of the priority of the Preferred shares, the expenses of the Offering will effectively be borne by holders of the Class A shares (as long as the net asset value per unit exceeds the Offering price per Preferred share plus accrued and unpaid distributions) and the net asset value per Class A share will reflect the expenses of the Offering of both the Preferred shares and Class A shares.

OTHER INFORMATION

On June 7, 2021, the Fund announced commencement of an at-the-market equity program (the "ATM Program") which allows the Fund to issue shares to the public from time to time, at the Fund's discretion. Any Class A shares or Preferred shares sold in the ATM Program will be sold through the Toronto Stock Exchange or any other marketplace in Canada on which the Class A shares and Preferred shares are listed, quoted or otherwise traded at the prevailing market price at the time of sale. The ATM expired on December 4, 2022 and was renewed December 7, 2022.

During the the Period, 44,300 Preferred shares were issued under the ATM Program at an average selling price of $10 per Preferred share. Gross proceeds, net proceeds and commissions on the Preferred shares issued were $445,120, $443,000 and $2,120, respectively.

On February 15, 2023, the Fund entered into an agreement with an agent to purchase the Fund's Class A shares for cancellation on the Toronto Stock Exchange. The Fund can purchase for cancellation a maximum of 293,494 Class A shares at the prevailing market price but at a price not greater than the most recent net asset value per share calculated prior to the repurchase.

During the the Period, 117,300 Class A shares were cancelled under the agreement at an average purchase price of $15 per Class A share. Gross proceeds, net proceeds and commissions on the Class A shares cancelled were $1,730,723, $1,730,723 and $0, respectively.

RECOMMENDATIONS OR REPORTS BY THE INDEPENDENT REVIEW COMMITTEE

The IRC tabled no special reports and made no extraordinary material recommendations to management of the Fund during the Period.

Big Pharma Split Corp.

FINANCIAL HIGHLIGHTS

The following tables present selected key financial information about the Class A shares of the Fund or the Fund and are intended to help you understand the Fund's financial performance for the Period and past annual periods. This information is derived from the Fund's annual audited financial statements.

THE FUND'S NET ASSETS PER UNIT	2023	2022	2021	2020	2019
Net assets - beginning of the period	**$ 15.40**	**$ 15.07**	**$ 14.11**	**$ 15.41**	**$ 14.05**
Increase (decrease) from operations					
Total revenue	0.56	0.60	0.59	0.83	0.67
Total expenses	(0.47)	(0.45)	(0.49)	(0.42)	(0.41)
Preferred share distribution	(0.42)	(0.50)	(0.53)	(0.48)	(0.47)
Preferred shares agent fees and issue costs	-	-	(0.15)	-	-
Premium (discount) on issuance of preferred shares	-	-	0.18	-	-
Realized gains (losses) for the period	2.07	2.00	(0.01)	2.21	1.43
Unrealized gains (losses) for the period	(2.27)	(0.07)	3.68	(2.36)	0.94
Total increase (decrease) from operations[1]	**$ (0.53)**	**$ 1.58**	**$ 3.27**	**$ (0.22)**	**$ 2.16**
Distributions[2]					
Dividends	(0.21)	(0.93)	(0.21)	(1.24)	(1.24)
Capital gains	(1.03)	(0.31)	(1.75)	-	-
Total annual distributions[2]	**$ (1.24)**	**$ (1.24)**	**$ (1.96)**	**$ (1.24)**	**$ (1.24)**
Net assets - end of period[1]	**$ 13.62**	**$ 15.40**	**$ 15.07**	**$ 14.11**	**$ 15.41**

RATIOS AND SUPPLEMENTAL DATA	2023	2022	2021	2020	2019
Total net asset value (including Preferred shares) (000's)	**$ 26,148**	**$ 29,585**	**$ 37,267**	**$ 22,533**	**$ 26,891**
Total net asset value - Class A shares (000's)	**$ 15,851**	**$ 19,731**	**$ 22,404**	**$ 13,185**	**$ 16,309**
Number of Class A shares outstanding (000's)	1,164	1,281	1,486	935	1,058
Management expense ratio[3] - Class A shares	6.04%	6.08%	8.36%	6.28%	6.45%
Management expense ratio before waivers or absorptions[3] - Class A shares	6.04%	6.08%	8.36%	6.28%	6.45%
Trading expense ratio[4]	0.12%	0.15%	0.15%	0.17%	0.18%
Portfolio turnover rate[5]	27.26%	26.24%	31.33%	45.91%	45.06%
Net asset value per unit[6]	**$ 23.84**	**$ 26.11**	**$ 25.07**	**$ 24.11**	**$ 25.41**
Net asset value per Class A share	**$ 13.62**	**$ 15.40**	**$ 15.07**	**$ 14.11**	**$ 15.41**
Net asset value per Preferred share	**$ 10.00**	**$ 10.00**	**$ 10.00**	**$ 10.00**	**$ 10.00**
Closing market price - Class A shares	**$ 13.75**	**$ 14.58**	**$ 14.67**	**$ 13.40**	**$ 14.05**
Closing market price - Preferred shares	**$ 9.70**	**$ 9.89**	**$ 10.60**	**$ 10.68**	**$ 10.48**

Explanatory Notes:

1. Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the reporting period. It is not intended that the Fund's net assets per unit table act as a continuity of opening and closing net assets per Class A share.

2. Distributions, if any, are paid in cash.

3. Management expense ratio ("MER") is based on total expenses (excluding commissions and other portfolio transaction costs) of the stated period and is expressed as an annualized percentage of the Class A daily average net asset value during the period.

   The Class A MER for the year ended December 31, 2019 excluding the Preferred share distribution was 2.94%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.66%. This MER excluding the Preferred share distribution was 1.67%.

   The Class A MER for the year ended December 31, 2020 excluding the Preferred share distribution was 2.80%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.65%. This MER excluding the Preferred share distribution was 1.63%.

   The Class A MER for the year ended December 31, 2021 includes agent fees of $359,681, issue costs of $119,421, accretion of premium on issuance of Preferred shares of $231,526 and Preferred share distributions of $687,381. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.26%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 7.01%. The MER based on the daily average of the total net asset value (including Preferred shares) was 4.91%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.91%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 4.12%.

   The Class A MER for the year ended December 31, 2022 includes agent fees of nil, issue costs of $6,520, accretion of premium on issuance of Preferred shares of $4,155 and Preferred share distributions of $756,020. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 2.76%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 6.07%. The MER based on the daily average of the total net asset value (including Preferred shares) was 3.68%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.67%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 3.67%.

The Class A MER for the Period ended December 31, 2023 includes agent fees of $nil, issue costs of $2,120, accretion of premium on issuance of Preferred shares of $2,120 and Preferred share distributions of $505,670. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.13%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 6.04%. The MER based on the daily average of the total net asset value (including Preferred shares) was 3.82%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.98%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 3.82%.

4. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value during the period. In 2020 the calculation was modified to include certain transaction costs charged by the custodian. The trading expense ratio in prior periods was not re-stated.

5. The Fund's portfolio turnover rate indicates how actively the Fund's portfolio advisor manages its portfolio investments. A portfolio turnover of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher a Fund's portfolio turnover rate, the greater the trading costs payable by the Fund and the greater the chance of an investor receiving taxable capital gains. There is not necessarily a relationship between a high turnover rate and the performance of a Fund.

6. Net asset value per unit as of the financial statement date is calculated by adding the net assets attributable to Class A shares and the redemption value of the Preferred shares and dividing the total by the average number of Class A and Preferred shares outstanding.

Big Pharma Split Corp.

PAST PERFORMANCE

The performance information presented herein assumes all dividends of the Fund during the periods presented were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemptions, or other charges that would have reduced returns or affected performance. Past performance of the Fund is not necessarily indicative of how it will perform in the future.

Year-by-Year Returns
The following charts present the Fund's performance for each of the years shown and illustrate how the Fund's performance varied for Class A and Preferred shares. The chart shows, in percentage terms, how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year.

Class A shares



2017 represents the period from November 24 to December 31

Preferred shares



2017 represents the period from November 24 to December 31

Big Pharma Split Corp.

Annual Compound Returns
The following table shows the annual compound returns for the Fund. All returns are in Canadian dollars, unless otherwise specified, on a total return basis, net of fees.

For comparison purposes, the MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)± is used. While the Fund uses this benchmark for long-term performance comparisons, it is not managed relative to the composition of this benchmark. As a result, the Fund may experience periods when its performance is not aligned with this benchmark, either positively or negatively. The return of this benchmark is calculated without the deduction of management fees and fund expenses whereas the performance of the Fund is calculated after deducting such fees and expenses. Please see the "Results of Operations" section of this report for a discussion on recent performance.

Investment Return %	1 Year	3 Years	5 Years	10 Years	Since Inception‡
Fund Performance Class A shares	-3.42	9.68	9.72	-	10.13
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)±	3.30	10.49	10.73	-	9.57
Fund Performance Preferred shares	5.09	5.09	5.09	-	5.10
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)±	3.30	10.49	10.73	-	9.57

‡ Since inception dates are: Class A shares – November 24, 2017; Preferred shares – November 24, 2017

Big Pharma Split Corp.

SUMMARY OF INVESTMENT PORTFOLIO

The major portfolio categories and top holdings of the Fund at the end of the Period are indicated in the following tables. A detailed breakdown of the Fund's holdings is available in the ''Schedule of Investments'' section of the Fund's annual audited financial statements.

As at December 31, 2023

Top Holdings	% of Net Asset Value
Amgen Inc.	17.3
Merck & Co., Inc.	17.0
AbbVie Inc.	16.8
Eli Lilly and Company	16.8
Zoetis Inc., Class A	16.3
Johnson & Johnson	16.1
Sanofi ADR	15.6
Bristol-Myers Squibb Company	15.5
AstraZeneca PLC ADR	15.5
Pfizer Inc.	14.2
Foreign currency forward contracts	4.5
Cash and other assets and liabilities	0.2
Options	(0.9)
Preferred shares	(64.9)
Total	**100.0**

This summary of investment portfolio may change due to the ongoing portfolio transactions of the Fund. Quarterly updates of the Fund's investment portfolio are available at **www.harvestetfs.com**.

SECTOR ALLOCATION

Sector	% of Net Asset Value
Health Care	161.1
Foreign currency forward contracts	4.5
Cash and other assets and liabilities	0.2
Options	(0.9)
Preferred shares	(64.9)
Total	**100.0**

GEOGRAPHIC ALLOCATION

Country of Risk	% of Net Asset Value
United States	130.0
France	15.6
United Kingdom	15.5
Foreign currency forward contracts	4.5
Cash and other assets and liabilities	0.2
Options	(0.9)
Preferred shares	(64.9)
Total	**100.0**

Big Pharma Split Corp.

Disclaimers

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in a Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

± Source: MSCI. Certain information contained herein (the "Information") is sourced from/copyright of MSCI Inc., MSCI ESG Research LLC, or their affiliates ("MSCI"), or information providers (together the "MSCI Parties") and may have been used to calculate scores, signals, or other indicators. The Information is for internal use only and may not be reproduced or disseminated in whole or part without prior written permission. The Information may not be used for, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user assumes the entire risk of any use it may make or permit to be made of the Information. No MSCI Party warrants or guarantees the originality, accuracy and/or completeness of the Information and each expressly disclaims all express or implied warranties. No MSCI Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Head Office

610 Chartwell Rd, Suite 204 Oakville, Ontario L6J 4A5
Phone Number: 416.649.4541
Toll Free: 866.998.8298
Fax Number: 416.649.4542
Email: info@Harvestportfolios.com